NCT03050060
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Read More at ClinicalTrials.govInvestigators: Ramesh Rengan, MD, PhD, FASTRO
1959 NE Pacific Street
Seattle, WA 98195
206.598.4100
1570 N 115th Street
Seattle, WA 98133
http://www.sccaprotontherapy.com/ 206.306.2800
Dr. Rengan is a Professor and Chair in the Department of Radiation Oncology at the University of Washington. Dr. Rengan specializes in the treatment of thoracic malignancies, ocular tumors, renal cell carcinoma, and prostate cancer.
“My philosophy is fairly simple—the patients come first. I try to spend time getting to know each patient from their initial visit through their entire journey through the treatment process. Each patient has distinct mental and emotional needs and I try to do my best to tailor my approach to suit those needs. That can only come from spending time and truly listening to the patient. Although, I may have greater medical knowledge about their disease, they have a far better understanding of their physical and emotional needs. In order to be successful in caring for the patient, a partnership must be forged between the oncologist and the patient, with each contributing to the development of a treatment plan that speaks to all of the needs of the patient.”
Medical Degree: University of Michigan Medical School, 2001
Doctoral Degree: University of Michigan Medical School, 2001
Residency: Radiation Oncology at Memorial Sloan-Kettering Cancer Center, 2006
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Read More at ClinicalTrials.govInvestigators: Ramesh Rengan, MD, PhD, FASTRO
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Read More at ClinicalTrials.govInvestigators: Ramesh Rengan, MD, PhD, FASTRO
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Read More at ClinicalTrials.govInvestigators: Ramesh Rengan, MD, PhD, FASTRO